HOOKIPA posts Q1 net income of $14.4M; revenue surges to $36.6M on Roche termination

HOOKIPA Pharma Inc.

2024-Q1 EPS reported $0.11 revenue$36,599,000

Revenue $36.6M (vs $3.2M YoY) mainly from accelerated recognition of Roche upfront and milestone payments.
Net income $14.4M vs net loss $19.7M in Q1 2023; cash $93.0M as of March 31, 2024.
HB-200 Phase 2/3 pivotal trial design aligned with FDA; first patient enrollment expected Q4 2024; PRIME designation from EMA.
HB-700 IND cleared for KRAS-mutated cancers; received $10M milestone from Roche; regained full IP control.
Mark Winderlich appointed Chief Development Officer effective April 1, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HOOKIPA Pharma Inc. reported first quarter ended March 31, 2024 results: revenue $36.6 million.

Period: first quarter ended March 31, 2024
Revenue: $36.6 million
Result: reported results

Exact text from the filing

Revenue was $36.6 million for the three months ended March 31, 2024, compared to $3.2 million for the same period in 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007462

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.